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Abstract
Background: Cardiovascular diseases continue to be a challenge and burden to heath. The incidence of type 2
diabetes is increasing. Modifying the (common) risk factors of them is the key of longterm success. The aim of the
study was to establish if the special composition of innovative food supplement Reg’Activ Cholesterol (RAC) has a
positive influence to the human body cardiovascular-inflammatory and diabetic parameters.
Methods: Forty-five clinically asymptomatic participants consumed an RAC containing an antioxidative and
antiatherogenic probiotic Lactobacillus fermentum ME-3 (LFME-3) for 4 weeks. The parameters measured
were total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride, oxLDL, hsCRP, IL-6 and glycosylated
haemoglobin (HbA1c%).
Results: The cardiovascular and diabetes risk profile of the participants improved significantly after 4 weeks
of the intervention. The reduction of total cholesterol (from 6.5 ± 1.0 to 5.7 ± 0.9 mmol/l, p = 9.90806E-11)
was on the account of LDL cholesterol as the HDL cholesterol level rose from 1.60 ± 0.31to 1.67 ± 0.34mml/l,
p = 0.01. HbA1c% was reduced from 5.85 ± 0.28 to 5.66 ± 0.25 p = 4.64E-05 and oxLDL decreased from 84 ± 20
to 71 ± 15 U/l, p = 4.66292E-08.
Conclusions: The consumption of RAC in clinically asymptomatic volunteers with borderline-high values of
risk factors for cardiovascular disease (BMI, HbA1c%, LDL cholesterol) for 4 weeks had a positive effect on
blood lipoprotein, oxidative stress and inflammatory profile. There are no human trials published before with
RAC.
Trial registration: The trial described here isa n open label pilot study within the framework of a larger
special clinical trial (ISRCTN55339917) [Accessed 20 Feb 2016].
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Background
Cardiovascular disease (CVD) performs the number one
cause of death worldwide and continues to be a major
economic and health burden globally [1]. Atherosclerosis
is the pathophysiological process underlying CVD. The
signals starting the diseases are not ultimately under-
stood and a role of an unbalanced intestinal microbiota
in atherosclerosis pathogenesis is discussed [2]. Among
the risk factors of CVD hypercholesterolemia and an
elevated level of blood triglycerides (TG) are generally
accepted. An elevated level of low-density lipoprotein
(LDL) is a major measurable risk factor for CVD thus
blood lipid lowering strategy has been a primary target
for both in primary and secondary cardiovascular disease
prevention to date [3]. The role of an elevated level of
oxidized LDL (oxLDL) in the pathogenesis of athero-
sclerosis is also stressed [4] thus all mechanisms leading
to extensive oxidation of the LDL particles are unfavor-
able from the point of view of CVD.
Inflammation and non-specific haemoglobin (Hb) gly-
cation are important pathogenetic factors of CVD and
diabetes. Abnormal Hb glycation (an elevated HbA1c%)
is linked to the pathophysiology of type 2 diabetes melli-
tus (T2DM) effect on CVD. A permanent low-grade (or
high-normal) inflammation (LGI) and an advanced
glycation both can enhance the development of CVD as
demonstrated in the ATTICA study that supported a
positive association between LGI and diabetes [5]. LGI
occurs typically in the vasculature and adipose tissue of
a subject and is chronic in its nature. The parameter
universally accepted to measure LGI is hsCRP [6]. It has
been shown that triglyceride/HDL-cholesterol ratio can
be used as a marker of insulin resistance (a prediabetes/
diabetes related marker) [7].
Although the study presented here is the first with
RegActive Cholesterol formula, the probiotic strain L.fer-
mentum ME-3 has been extensively tested both in
humans and animals. Lactobacillus fermentum ME-3
(DSM 14241) (LFME-3) is a strain of human origin
isolated from a healthy child [8]. The strain has both
antimicrobial and antioxidative functional properties in-
cluding the complete glutathione system [9–11]. Several
benefits for health of fermented products containing
LFME-3 have been demonstrated in various clinical
studies including a favorable impact on postprandial
lipemia and oxidative stress status [12–15]. Reg’Activ
Cholesterol™ (VF Bioscience) has been formulated for
promoting cardiovascular health. This innovative formu-
lation combines LFME3 with others functional ingredi-
ents that are listed and described in the Materials
section.
The aim of the study was to establish if a special for-
mulation of Reg’Activ Cholesterol (RAC) comprising
also LFME3 has a positive influence to the human body
cardiovascular, inflammatory and diabetic parameters
LDL cholesterol, TG, oxLDL, hsCRV, IL-6 and glycated
haemoglobin (HbA1c%).
Materials and methods
Participants (subjects) and study design
Within the framework of a larger clinical trial
(ISRCTN55339917) [16] forty five clinically healthy vol-
unteers with borderline values for risk factors for cardio-
veascular diasease were recruited into a preliminary,
open label study (Table 1).
The needed sample size was calculated based on our
previous experiments: if the difference in a parameter
changes clinically significantly for at least 50 % of partic-
ipants, it should show also a statistically significant
difference between controls and the intervention/sup-
plemented group. In our experiment the main param-
eters of interest (thus being the primary outcome
measures) were the amount of LDL cholesterol,
oxLDL and HbA1c %.
In the recruitment phase (open public call to partici-
pate) the inclusion criteria were age 50–75 years, BMI
24–30, clinically healthy (asymptomatic). The exclusion
criteria were: a history of gastrointestinal disease, dia-
betes, food allergy, use of any antimicrobial agent or
probiotics or an acute infection within the preceding
2 months; use of any regular concomitant medication in-
cluding any non-steroidal anti-inflammatory drugs and
antioxidant products or probiotics within at least the
preceding 2 weeks; pregnancy or breastfeeding; any ser-
ious organ or systemic disease, eating disorder, extensive
exercise, genetic hyperlipidemia, drug or alcohol abuse,
smoking, active weight loss > 5 kg in prior 3 months;
participation in other studies within the last 30 days/
during the study and no wish to participate. Then the
HbA1c was measured (2 weeks before the actual inter-
vention/test period started) and the participants with
HbA1c value between 5.7–6.2 (the value 5.7 being the
lower end for prediabetes diagnostic criteria and al-
though the upper value for prediabetes is 6.4 we consid-
ered 6.2 for our study to be more suitable to exclude
possible undiagnosed diabetics) were included into the
study. The participants were asked not to change their
diet habits during the investigation period.
Table 1 General data of 45 healthy volunteers in the open label
study
Indices Clinically healthy volunteers, n = 45
An open label preliminary study
Sex (female/male) 35/10
Age 50–75
Body mass index (kg/m2) 26 ± 2.5
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All participants signed their written informed consent
and had the option of withdrawing from the study at
any time. The Ethics Review Committee (ERC) on
Human Research of the University of Tartu approved
the study protocol. This study was carried out in accord-
ance with the Declaration of Helsinki of the World
Medical Association.
Each participant was evaluated for anthropometrical in-
dices. Body mass index (BMI) was calculated as the weight
(kg) divided by squared height (m2) [17]. The samples of
fasting blood for the analysis set were collected two times:
at the beginning and at the end of the trial period of
administration of LFME3 containing capsules RAC for
4 weeks 2 capsules/day. The plasma samples were col-
lected after an overnight fast and abstinence from any
medications, tobacco, alcohol and tea or coffee. Samples
were kept at −80 °C until analyzed.
RAC has been formulated for promoting cardiovascu-
lar health. This innovative formulation combines LFME3
with others functional ingredients that have been used
in food supplements due to their antioxidative properties
(Table 2).
The strain LFME-3 is deposited in the Deutsche
Sammlung von Mikroorganismen und Zellkulturen
(German Collection of Microorganisms and Cell Cul-
tures GmbH) under registration number DSM 14241.
Molecular identification of the strain as LFME3 was
confirmed by internally transcribed spacer polymerase
chain reaction and 16SrRNA sequencing [18].
The markers for determination of the cardiovascular
health were selected according to the suggestions by the
NDA of European Food Safety Authority [19].
Measurement of biochemical parameters
Oxidized LDL
To measure oxidized LDL (oxLDL) the ELISA kit (Cat.
No. 10-1143-01, Mercodia AB, Uppsala, Sweden) was
used [20]. The solid phase two-site enzyme immuno-
assay is based on the direct sandwich technique in which
two monoclonal antibodies are directed against separate
antigenic determinants on the oxidized apolipoprotein B
molecule. During incubation oxidized LDL in the sam-
ple reacts with anti-oxidized LDL antibodies bound to
micro titration well. After washing a peroxidase con-
jugated anti-human apolipoprotein B antibody recog-
nizes the oxLDL bound to the solid phase. After a
second incubation and washing the bound conjugate
was detected by reaction with 3,3’,5,5’-tetramethylben-
zidine. The reaction is stopped by adding acid and
the intensity of the color was measured spectrophoto-
metrically at 450 nm and the results were presented
as U/L.
Analyses of metabolic indices (plasma glucose and
lipids: total cholesterol, LDL cholesterol, HDL choles-
terol, IL-6, TG, hsCRP and HbA1c% were performed
with standard laboratory methods using certified assays
in the United Laboratories of the Tartu University Hos-
pital, Estonia. Intervals for routine laboratory tests pro-
posed by the Nordic Reference Interval Project [21]
were used as references.
Statistical analysis
Calculations were performed using commercially
available statistical software packages (Statistics for
Windows, Stat Soft Inc. and Graph Pad PRISM Ver-
sion 2.0). All values are given as mean and standard
deviation (mean ± SD). Statistically significant differ-
ences between the values before and after consump-
tion of LFME-3 containing capsules were determined
by using Student’s t-test. In all analyses, p values
<0.05 were considered to be statistically significant.
Results
The level of LDL cholesterol as well as total cholesterol
and oxLDL decreased significantly in all participants and
HDL cholesterol showed a tendency of improvement
after 4 weeks of consumption of LFME3 containing food
supplement RAC (Table 3). The level of inflammatory
markers hsCRP and IL-6 as well as the level of HbA1c%
decreased significantly after 4 weeks of administration of
RAC. The use of RAC also declined the insulin resist-
ance marker TG/HDL cholesterol ratio (Table 3).
Discussion
The limitations of our study design are mainly attribut-
able to the lack of using a standardized diet prior and
during the intervention. By using quite strict exclusion
criteria we tried to minimize the influence of diet.
The elevated LDL cholesterol and blood triglyceride
levels are well accepted risk factors of CVD [3]. Inflam-
mation and elevation of HbA1c% are related to
Table 2 The composition of the Reg’Active Cholesterol Capsule
Ingredients Quantity per recommended
daily dose (2 capsules)
% of RDA
Red Yeast rice 666 mg (10 mg monacolin K) -
Lactobacillus fermentum ME-3 60 mg (equals 6x 109 LAB) -
Ubiquinol (Kaneka QHTM) 30 mg -
L-cysteine 30 mg -
Vitamin E 10 mg 83 %
Vitamin B1 0.66 mg 60 %
Vitamin B6 1 mg 72 %
Vitamin B9 100 μg 50 %
Vitamin B12 1.5 μg 60 %
Other ingredients: maltodextrin (filling agent), magnesium salts of fatty acids
(anti-caking agent), silica dioxide (anti-aggregating agent), vegetable capsule
(hydroxyl-propyl-methyl-cellulose), soy lecithin
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pathogenesis of both CVD and diabetes [5]. An elevated
level of oxLDL has a role in the pathogenesis of athero-
sclerosis [4]. Thus additional good tools to control blood
lipoprotein, oxidative stress and inflammatory profile are
needed. This study investigated a special formulation of
food supplement RAC and established positive effects
on blood lipid profile, oxidized LDL level, inflammatory
signature, HbA1c% and TG/HDL cholesterol ratio.
The creation of an innovative formulation RAC with
different bioactive components was based on the previ-
ously obtained scientific information.
Gut microbiota forms an essential part of the complex
ecosystem of the host that is involved in nutrition and
health. A wide variety of host, microbiological, dietary
and environmental factors affect the metabolic interrela-
tions between gut mucosal epithelial cells and micro-
biota [22–25]. Organisms obtain a portion of cholesterol
through nutrition and the major part is produced by
highly-regulated biosynthesis in human body while dom-
inating amount of cholesterol is eliminated from the
organism as bile acids [26]. Among normal microbiota
of gastrointestinal tract some species and strains of lactic
acid bacteria are able to assimilate cholesterol from pro-
vided dietary products [27]. A meta-analysis of 13
probiotic studies indicates that a diet rich in probiotics
decreases total cholesterol and LDL cholesterol concen-
tration in plasma for participants with high, borderline
high and normal cholesterol levels [28]. However, its
relation to temporal colonization of digestive tract by
probiotic strains and the duration of treatment remains
to be evaluated.
Earlier studies have shown that the impact of probio-
tics on lipid metabolism markers of the host can be
quite strain and host specific [29, 30]. The anti-oxidative
and anti-atherogenic effect of LFME3 has been described
previously in numerous in vitro and human trials with
different dairy products such as goat milk, cheese and
yoghurt [9, 12, 13, 15].
Insulin resistance is associated with cardiovascular dis-
ease pathogenesis. The evidence is piling up that he TG/
HDL ratio can be used as a parameter to evaluate insulin
resistance [7, 31–33]. After consumption of RAC capsules
the TG/HDL cholesterol ratio decreased significantly.
Our previous data from 8 weeks versus data from
4 weeks showed that consumption of LFME3 enriched
kefir, but not the placebo kefir, significantly decreased
the level of LDL cholesterol [34]. Next, only the pro-
biotic kefir in 8 weeks decreased significantly the ratio of
TG/HDL cholesterol.
Thus, these data together show that compositions
comprising LFME-3 help to prevent risk, alleviate the
symptoms and treat metabolic syndrome related condi-
tions (prediabetes, diabetes, cardiovascular disease).
Recently we found that using LFME3 causes a decline
of blood level of myeloperoxidase (data not published)
accepted as one of the main factors causing production
of dysfunctional HDL particles [35].
Probably, there exist different mechanisms which lead
to the positive effects of lactobacilli on various markers
of lipid metabolism in human body [2, 36].
It is well known that during the passage of the upper part
of intestinal tract probiotics have an ability to bind a certain
amount of bile acids which leads to the loss of this amount
from the enterohepatic recirculation. As a consequence, the
liver elevates de novo production of new bile acids from
cholesterol favoring a reduction of cholesterol levels. Some
other possible mechanisms are as follows: LFME3 is char-
acterized by a good activity of glycosyl-hydrolases, like
alpha-galactosidase, beta-galactosidase, alpha-glycosidase,
beta-glycosidase and beta-glycoronidase [37]. When LDL
cholesterol levels are elevated a part of it is oxidized and
subsequently taken up by the arterial wall to form athero-
sclerotic plaques. However, the cholesterol transport system
based on HDL is responsible for facilitating the movement
of cholesterol from tissues back to the liver.
The RAC contains monacolin K that is an inhibitor of
cholesterol synthesis key-enzyme [38, 39]. The RAC for-
mula also contains vitamin E and ubiquinol (vitamin Q),
Table 3 The cardiovascular markers and an insulin intolerance
parameter (TG/HDLChlesterol) in 0 week and after 4 weeks




0 week 4 weeks
Cholesterol (mmol/l) 6.5 ± 1.0 5.7 ± 0.9
p = 9.90806E-11
LDL cholesterol (mmol/l) 4.5 ± 0.9 3.7 ± 0.8
p = 2.30351E-10
HDL cholesterol (mmol/l) 1.60 ± 0.31 1.67 ± 0.34
p = 0.01
TG (mmol/l) 1.6 ± 0.4 1.4 ± 0.4
p < 0.003
TG/HDL cholesterol 1.06 ± 0.43 0.88 ± 0.35
p = 0.0002
hs CRP (mg/l) 2.9 ± 2.0 2.0 ± 1.0
p = 0.007
HbA1c % 5.85 ± 0.28 5.66 ± 0.25
p = 4.64E-05
oxLDL U/l 84 ± 20 71 ± 15
p = 4.66292E-08
IL-6 (pg/ml) 2.2 ± 0.9 1.7 ± 0.5
p < 0.00185
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both working in the human body as powerful antioxi-
dants. A study by Ceriello and colleagues also demon-
strated the beneficial effects of targeting hyperglycemia
and oxidative stress (OxS) and endothelial dysfunction
simultaneously using insulin and an antioxidant (vitamin
C) [40]. Targeting hyperglycemia and OxS simultan-
eously may help to ameliorate lipid abnormalities (e.g.,
elevated LDL levels) [41], and improve OxS which
increases the susceptibility of LDLs to oxidation and
glycation. This may prevent atherosclerosis and endothe-
lial dysfunction. Food cysteine is the rate-limiting factor
in cellular glutathione (GSH) biosynthesis. GSH, a well
known cellular antioxidant and regulator of many body
functions, is synthesized in the body from the amino acids
L-cysteine, L-glutamic acid, and glycine. The sulfhydryl
group of cysteine serves as a proton donor and is respon-
sible for its biological activity. Thus, RAC contains L-
cysteine and besides that LFME3 can transport and
synthesise glutathione and has the ability of redox cycling
of glutathione [11, 42]. Vitamins B1, B6, B9 and B12 have
several widely known effects in human body, including
improvement of overall energy workout, carbohydrate,
lipid and amino acids (e.g. homocysteine) metabolism.
The capsule RAC has been specially formulated to im-
prove cardiovascular health. The decline of IL-6 and
hsCRP refer to an improvement of blood inflammatory
status. However, it seems that such formula/composition
might have an impact on cardiometabolic risk involving
also prediabetes/diabetes. The triglyceride/HDL choles-
terol ratio is a marker of insulin resistance (a prediabe-
tes, diabetes related marker). We found that after
consumption of RAC capsules the TG/HDL-Chol ratio
decreased significantly. The data of our preliminary
study show that there was also a decline in HbA1c%, a
well accepted marker for prediabetes/diabetes. Of course
the antidiabetic effect should be verified using longer
randomized placebo controlled double blind trials.
Gastrointestinal OxS is associated with the non-specific
glycation, which in turn may influence the long term level
of blood sugar. Through the OxS and inflammation on
the cellular level the up-regulation of pro-inflammatory
cytokines may reduce glucose transporter type 4 (GLUT4)
expression and translocation to the plasma membrane in
human adipocytes and muscle cells, which may lead to
the decreased insulin-stimulated glucose uptake [43, 44].
There are limitations of intensive treatment of hypergly-
cemia in preventing diabetic complications, because of
adverse effects, which are linked to OxS. Maybe the simul-
taneous targeting of hyperglycemia and OxS could be
more effective than intensive treatment of hyperglycemia
in the management of T2DM [45]. A reduction in OxS
and simultaneous cardiovascular risk factor control seems
to be an ideal treatment strategy in T2DM patients [46].
Aside pharmaceutical and lifestyle correcting measures
there is definitely room for food supplements and func-
tional foods in the complex management of CVD and
T2DM [4, 28].
Conclusions
The consumption of RAC capsules in asymptomatic vol-
unteers with borderline values of risk factors for cardio-
vascular disease (BMI, HbA1c%, LDL cholesterol) for
4 weeks had a positive effect on blood lipoprotein,
oxidative stress and inflammatory profile.
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